# NOMAD Power Solutions, Inc. (NMAD)

> Source: Nexqual · https://nexqual.com/NMAD · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, NOMAD Power Solutions, Inc. (NMAD), nexqual.com/NMAD" · informational, not investment advice.

**Price:** USD 3.81 (+5.83% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 3.6 · day 3.5–3.84 · 52w 2.36–8.38 · market cap $61.3M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -12.0% vs S&P 500 +13.4%; 5Y -79.7% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$5.1M | -$8.0M |
| Net income | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.1M | -$8.9M |
| EPS (diluted) | -$5.00 | -$3.99 | -$2.66 | -$1.59 | -$1.26 | — |
| Cash + short-term investments | $4.8M | $5.4M | $4.2M | $1.0M | $5.1M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.6x · Earnings yield -14.55%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -12.0% | -79.7% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -12.1% | -27.4% |
| Volatility (annualized) | 93.6% | 118.5% |
| Max drawdown | -59.3% (Jun 2026→Sep 2026) | -96.7% (Jan 2022→Jun 2025) |

## Peers (Electrical Equipment & Parts)
KE (Kimball Electronics, Inc.) USD 24.6 -1.62% · ENVX (Enovix Corporation) USD 2.79 +9.41% · EOSE (Eos Energy Enterprises, Inc.) USD 1.73 +1.17% · TE (T1 Energy Inc.) USD 2.29 -0.87% · ADSE (ADS-TEC ENERGY PLC) USD 9.7 +1.57% · FCEL (FuelCell Energy, Inc.) USD 11.11 -4.06%

## More
Full page: https://nexqual.com/NMAD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in NMAD's own 10-K filed 2026-03-31 (https://www.sec.gov/Archives/edgar/data/1335105/000149315226014052/form10-k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | GSK | "December 23, 2025 we announced that we are going to expand the enrollment of the trial from 21 to 42 patients in collaboration with GSK," |
| Competitor | Siemens | "primary competitors in the proton therapy market are IBA Worldwide, Varian Medical Systems (Siemens Healthineers), Hitachi, Mevion" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |